ArticleJournal for immunotherapy of cancer2022

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.

Ilana Mandel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.